Document Detail


Inhaled treprostinil for the treatment of pulmonary arterial hypertension.
MedLine Citation:
PMID:  22135338     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Pulmonary arterial hypertension is a progressive disease characterized by vascular proliferation and vasoconstriction of the small pulmonary arteries that eventually leads to right-sided heart failure and death. Patients often initially have symptoms such as shortness of breath, fatigue, and edema; later in the disease, presyncope and syncope are common. Patients with progressive pulmonary arterial hypertension despite oral therapy and/or with severe disease typically require treatment with a prostanoid. Inhaled treprostinil (Tyvaso) is a prostacyclin analog indicated for the treatment of pulmonary arterial hypertension to increase walk distance in patients with symptoms classified as New York Heart Association functional class III. Inhaled treprostinil was approved by the Food and Drug Administration in July 2009. This article provides a brief overview of the pathophysiology of pulmonary arterial hypertension and reviews the mechanism of action, key clinical data, and the practical management of inhaled treprostinil in patients with pulmonary arterial hypertension.
Authors:
Abby Poms; Martha Kingman
Related Documents :
22015568 - 2009 esc/ers pulmonary hypertension guidelines and connective tissue disease.
21914448 - C-122, a novel antagonist of serotonin receptor 5-ht(2b), prevents monocrotaline-induce...
22035778 - Mechanisms of pulmonary hypertension related to ventricular septal defect in congenital...
10347258 - Cryopreserved arterial homografts: preliminary results in infrageniculate arterial reco...
18727978 - Heavily calcified chronic total occlusion of common iliac artery successfully treated w...
937058 - Effect of lung irradiation on the incidence of pulmonary metastases and its mechanism.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Critical care nurse     Volume:  31     ISSN:  1940-8250     ISO Abbreviation:  Crit Care Nurse     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-12-02     Completed Date:  2012-04-26     Revised Date:  2012-05-14    
Medline Journal Info:
Nlm Unique ID:  8207799     Medline TA:  Crit Care Nurse     Country:  United States    
Other Details:
Languages:  eng     Pagination:  e1-10     Citation Subset:  N    
Affiliation:
Duke University Medical Center, Durham, North Carolina 27710, USA. krich001@mc.duke.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Inhalation
Antihypertensive Agents / administration & dosage*
Epoprostenol / administration & dosage,  analogs & derivatives*
Humans
Hypertension, Pulmonary / drug therapy*,  physiopathology
Medical Illustration
Randomized Controlled Trials as Topic
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/treprostinil; 35121-78-9/Epoprostenol
Comments/Corrections
Erratum In:
Crit Care Nurse. 2012 Apr;32(2):11

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Using a nursing productivity committee to achieve cost savings and improve staffing levels and staff...
Next Document:  Critical care staff nurses: empowerment, certification, and intent to leave.